Swiss ingredient maker Lonza says its expansion in biologics manufacturing, including a new plant in the U.S., continues to build momentum and helped it realize revenue growth in the first half of the year. But costs at its massive operations in Visp, Switzerland, continue to be a drag and will result in the loss of more jobs there.
While U.S. drugmaker Alexion is building up its manufacturing operations in Europe, French CMO Lonza will do the same for Alexion in the U.S.
With drugmakers seeing the potential of targeted drug therapies, contractors are looking for ways to cash in on their needs. Swiss bioservices company Lonza says it has a new facility underway in the U.S. to make viral therapy products, an area where it sees lots of upside.
Growth in areas like antibody drug conjugates helped Lonza's Pharma & Biotech segment turn in more than 15% growth for the year and, in turn, helped the entire company realize one of its recovery goals a full year ahead of schedule, the Swiss company said Wednesday.
Swiss ingredient maker Lonza figures that if you can get in early with a winner, the rewards will be a lot greater. That is what happened when it became the supplier to manufacture Pharmacyclics' leukemia drug Imbruvica. And so instead of trying to strike a deal with each promising startup, it is turning to their source of funds, the venture capital crowd.
Swiss-based CMO Lonza is cutting its tax liability here through the blessing of local economic development. It is not being required to return any of the tax incentives it got for a plant expansion after deciding to abandon a Massachusetts manufacturing site.
French contract manufacturer Novasep says that its expansion of its highly potent active pharmaceutical ingredients manufacturing operations at its plant in Le Mans, France, is complete, signed off on by the FDA and now being scaled up for commercial use.
The Swiss drug ingredient and chemicals maker Lonza has said it's targeting pharma and biotech for growth, as companies increasingly farm out manufacturing. But so far, its pharma unit is suffering.
Swiss drug ingredient and chemical maker Lonza has reorganized its drug ingredient and custom pharma manufacturing units and is closing a U.S. plant to reduce costs, but so far the move has resulted in lower sales in pharma.
After months of regulatory woes and declining demand, Lonza is planning to cut two-thirds of its staff at a Massachusetts biologics plant, part of the CMO's overall effort to restructure and adapt to a changing market for commercial manufacturing.